Tag: Decentralized Clinical Trials

Decentralized Clinical Trial Platforms PEAK Matrix® Assessment 2023 – Update

Decentralized Clinical Trial Platforms  

Decentralized Clinical Trials (DCTs) are transforming the landscape of clinical research by harnessing digital technologies to facilitate remote patient participation. This patient-centric approach not only benefits participants but also ensures more inclusive and robust study results while reducing the workload for investigators. In the post-pandemic climate, a hybrid model is emerging that seamlessly integrates technology advances with traditional site workflows, creating a new era of clinical trials that harnesses the strengths of both. In a funding-constrained environment, DCT platform providers are looking to strike a balance between client satisfaction and cost reduction. They are focusing on delivering comprehensive solutions that include real-world evidence, integration with sensors and wearables, and tools dedicated to enhancing patient engagement and retention throughout the trial process.

Decentralized Clinical Trial Platforms PEAK Matrix® Assessment 2023 – Update

What is in this PEAK Matrix® Report

In this report, we assess the capabilities of 22 platform providers specific to the decentralized clinical trial landscape. These platform providers are mapped on the Everest Group PEAK Matrix®, a composite index of a range of distinct metrics related to a provider’s capability and market impact.
 

In this report, we:

  • Examine the provider landscape for DCTs
  • Assess DCT platform providers on several capabilities and market success-related dimensions

Scope

  • Industry: Life sciences clinical development technology
  • Geography: global

Related PEAK Matrix® Assessments

APSPM2024
PEAK Matrix®

Application Management Services for Mid-market Enterprises PEAK Matrix® Assessment

AWS Services Specialists
PEAK Matrix®

AWS Services Specialists PEAK Matrix® Assessment 2024

Salesforce Services
PEAK Matrix®

Salesforce Services PEAK Matrix® Assessment 2024

Conversational AI for IT Management
PEAK Matrix®

Conversational AI for IT Management – Products PEAK Matrix® Assessment 2024

Our Latest Thinking

India IT services
Blog

Everest Group Talent Demand Growth Index

GettyImages 530281555
Blog

Services Industry Growth is Bottoming Out, but How Much Does It Matter?

GettyImages 653836738
Blog

Boosting Project Readiness in Technology Talent: A Comprehensive Framework for Developing Project-Ready Workforce

GettyImages 1443890653
Blog

Exploring the Importance of Post-quantum Cryptography: An Unbreakable Vault to Protect Enterprises Against Advanced Cyberattacks, Part 2

What is the PEAK Matrix®?

The PEAK Matrix® provides an objective, data-driven assessment of service and technology providers based on their overall capability and market impact across different global services markets, classifying them into three categories: Leaders, Major Contenders, and Aspirants.

LEARN MORE ABOUT Top Service Providers

Decentralized Clinical Trials: What You Need to Know to Unlock Value | Webinar

On-Demand Webinar

Decentralized Clinical Trials: What You Need to Know to Unlock Value

Decentralized clinical trials (DCTs) were a boon during the pandemic. Pharmaceutical enterprises capitalized on the opportunity to conduct remote and virtual trials during a time when isolation was critical. However, in 2023, pharmaceutical enterprises are turning their focus to address new challenges such as scale, data security, and site engagement.

In this webinar, we’ll present insights on the trends pharmaceutical enterprises should expect this year, along with data from our 2023 DCT Platforms PEAK Matrix® assessment to shed light on both the demand and supply side of this market.

Our speakers will discuss:

  • How is the DCT technology market evolving and what does adoption look like across therapy areas and geographies?
  • What sourcing criteria should pharmaceutical enterprises consider for evaluating their DCT needs?
  • What are the supply landscape characteristics and their value propositions?

Who should attend?

  • CEOs, CMOs, CDOs, CTOs
  • Heads of Product Marketing
  • Chief Strategy Officers
  • Chief Commercial Officers
  • Chief Innovation Officers
  • Chief Scientific Officers
  • Heads of Strategy
  • Heads of Analyst Relations
  • Heads of Product Development
  • Heads of Innovation
  • Sourcing Heads
Satija Chunky
Vice President
Shah Nisarg
Practice Director

Everest Group Declares “The Age of Decentralized Clinical Trials Has Begun”

Everest Group also joins DTRA, offering members accessibility to pioneering research on clinical technology

 

DALLAS, March 29, 2023 —Everest Group today released its latest research report on Decentralized Clinical Trials, which documents a 38% increase from 2021 to 2022 in the number of trials conducted with a decentralized and/or virtual component. Everest Group predicts that the adoption of DCTs by pharmaceutical companies will rapidly accelerate as early adopters praise the approach for putting patient experience at the forefront.

DCTs enable patients to participate in a clinical trial from the comfort of their homes through the use of technology (such as sensors or remote monitoring devices) and home-visit services. In an Everest Group survey of buyers of DCTs, interviewees reported that 20-25% of their trial portfolios were decentralized or hybrid in nature today, but that 80-90% of their trial portfolios will be decentralized/hybrid by 2027. When asked to name the biggest benefit of DCTs, two out of three of those buyers interviewed (67%) cited “improved patient enrollment and retention rates.” Other benefits named include reduced cost (20%), reduced trial timelines (13%), more diverse patient populations (13%), getting real time data (7%), and enabling complex scoring and analysis (7%).

These findings and more are detailed in the Decentralized Clinical Trials Adoption Playbook. This playbook looks at more than 50 DCT case studies across different therapy areas and informs enterprises about the trends, benefits and challenges in DCT adoption to help them design a strategy for seamless DCT adoption. (A complimentary abstract of this report is available for download.)

Everest Group also released today its 2023 Life Sciences Decentralized Clinical Trial Platforms State of the Market Report, which analyzes the current state of the DCT market. The report explores adoption and market trends; the DCT platform providers’ landscape; the enterprise view of DCT platform providers; Environment, Social, and Governance (ESG) initiatives; and emerging technology opportunities in the industry. (A complimentary abstract of this report is available for download.)

Pandemic Spotlight on DCTs Revealed Major Benefits to the Approach

Traditional clinical trials are an expensive affair, costing upwards of US$2.6 billion and up to 12 years in research effort before approval by a regulatory body. Additional burdens of the traditional approach are patient recruitment challenges, patient adherence and engagement challenges, and regulatory challenges.

During the COVID-19 lockdowns, clinical trial activity came to a halt because patients could no longer travel to hospital networks to participate in a clinical trial. Fortunately, DCTs breathed new life into these paused clinical trials and delivered a host of benefits beyond those offered by the traditional clinical research approach. As a result, enterprises have accelerated their plans toward DCT adoption, looking to convert their piecemeal deployments into a comprehensive strategy aimed at enhancing the trial experience for patients, sponsors and Contract Research Organizations. Additionally, recent technological advances, the proliferation of wearables, and the regulatory pressure on the industry to adopt DCTs following the pandemic have made the DCT landscape ripe for disruption.

Everest Group Partners with DTRA

Everest Group also announced today that it has joined the Decentralized Trials Research Alliance (DTRA) to support the organization’s mission of advancing policies, research practices and new technologies to make clinical trial participation widely accessible.

“Today, pharmaceutical companies are optimistic about and investing in DCT trials, and Everest Group sees great potential in the market; however, because the technology and adoption is nascent, additional stakeholder education, product innovation and partnerships are needed,” said Nitish Mittal, partner at Everest Group. “DTRA is one of the few bodies which is driving standardization in the process and stakeholder education in this space. We’re pleased to support the DTRA mission and to contribute by giving DTRA members access to Everest Group’s curated clinical development technology research.”

A frontrunner in the research of clinical technology, Everest Group has a deep research portfolio focused on the demand and supply side of DCTs. By partnering with DTRA, Everest Group aims to disseminate information about the DCT market (such as DCT product suppliers and their capabilities, enterprise DCT adoption trends and sourcing considerations, DCT state of the market, etc.) to various stakeholders responsible for adoption and continued success of DCTs.

About Everest Group

Everest Group is a leading research firm helping business leaders make confident decisions. We guide clients through today’s market challenges and strengthen their strategies by applying contextualized problem-solving to their unique situations. This drives maximized operational and financial performance and transformative experiences. Our deep expertise and tenacious research focused on technology, business processes, and engineering through the lenses of talent, sustainability, and sourcing delivers precise and action-oriented guidance. Find further details and in-depth content at www.everestgrp.com.

Decentralized Clinical Trial Platform PEAK Matrix® Assessment 2023

Top Decentralized Clinical Trial Platforms

Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, flexibility in operations, and improved data quality. Before the pandemic, although the technology and data to support DCTs existed, only a few pilots were conducted. Today, the pressing need for remote patient- and site-centric trials has increased investments in DCTs by pharma enterprises, and the momentum is expected to accelerate going forward, indicating that DCTs are here to stay. Additionally, technology advances, innovative business models, increased wearables support, US FDA’s push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape.

In this report, we assess the capabilities of 24 DCT platform providers. The providers are positioned on Everest Group’s PEAK Matrix®, a composite index of a range of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other.

DOWNLOAD THE FULL REPORT Decentralized Clinical Trial Platforms PEAK Matrix® Assessment 2023

What is in this PEAK Matrix® Report:

In this report, we examine the provider landscape for DCTs and assess DCT platform providers on several capabilities and market success-related dimensions.

Scope:

  • Industry: life sciences

  • Geography: global

LEARN MORE ABOUT Decentralized Clinical Trial Platforms PEAK Matrix® Assessment 2023

Our Thinking

Choosing the Right Large Language Model (LLM) for Life Sciences Enterprises
Market Insights™

Choosing the Right Large Language Model (LLM) for Life Sciences Enterprises

Top Gen AI Use Cases Across the Life Sciences Value Chain
Market Insights™

Top Gen AI Use Cases Across the Life Sciences Value Chain

Mid-market Life Sciences Enterprises’ Service Provider Selection Criteria
Market Insights™

Mid-market Life Sciences Enterprises’ Service Provider Selection Criteria

Mid-market Life Sciences Enterprises Have Unique Demands for Their Service Providers
Market Insights™

Mid-market Life Sciences Enterprises Have Unique Demands for Their Service Providers

What is the PEAK Matrix®?

The PEAK Matrix® provides an objective, data-driven assessment of service and technology providers based on their overall capability and market impact across different global services markets, classifying them into three categories: Leaders, Major Contenders, and Aspirants.

LEARN MORE ABOUT Top Service Providers

Can You Hear Me Now — How Patient Voice Can Reshape Trial Design for Diversity and Inclusion | Webinar

Chunky Satija, Vice-President at Everest Group, will join other industry experts in this webinar to discuss the evolving role of patient voice and diversity and specific strategies to apply to clinical study or pipeline.

Attendees will gain a foundational understanding of broad market trends, clarity on how technology is specifically enabling data-driven insights into study-specific populations, and hear about the real world impact on patients.

Register for the webinar

When

Tuesday, May 24, 2022, at 11:00 am CDT, 12:00 pm EDT, 4:00 pm GMT, 9:30 pm IST

Where

Live, virtual event

Presenters

Chunky Satija
Vice-President, Everest Group

Noah Goodson
PhD, Decentralized Study Design Lead, THREAD Research

Fabio Gratton
Cofounder and CEO of inVibe Labs, a Division of THREAD

Dima Hendricks
Sickle Cell Health Coach, University of Pittsburgh

Register for the webinar

Understanding Strategic Investments by Decentralized Clinical Trials (DCT) Product Vendors | Blog

COVID-19 put the spotlight on Decentralized Clinical Trials (DCTs) that will last well beyond the pandemic-stricken years as the industry increasingly adopts digital solutions for conducting remote, virtualized, or decentralized trials. In this digital ecosystem, vendors need to focus on several strategic areas to provide a holistic DCT experience and stay ahead of the competition. Discover in this blog the five priorities that can help product vendors take the lead in the DCT ecosystem.

Decentralized clinical trials rose to popularity during the pandemic. As people around the world were advised to stay indoors, sponsors and Clinical Research Organizations (CROs) scrambled for an alternative solution. DCTs catapulted to the mainstream and disrupted the clinical trial landscape.

DCTs offer reduced dependency for on-site visits, increased patient convenience, and improved insights from real-time patient data. While the pandemic may slowly subside with increased vaccinations, decentralized trials are here to stay – continuously elevating the trial experience for patients, sponsors, and investigators.

Everest Group’s Decentralized Clinical Trial Products PEAK Matrix® Assessment 2021 found improving patient recruitment and retention are the top reasons behind sponsors adopting DCT solutions.

With DCT adoption growing significantly, sponsors have varied sourcing criteria based on their priorities. We have observed that large biopharma companies prefer a unified platform while mid-and small-sized players are more interested in cost as their top sourcing criteria for DCT vendors.

Biopharma companies want vendors who feel the market pulse and offer tailor-made deal solutioning for increased DCT adoption, as illustrated below.

Sourcing criteria for selecting DCT vendors

Slide1

Five focus areas for DCT vendors to enhance their value proposition

To increase DCT adoption and run trials holistically, sponsors and CROs require matured technology products as well as auxiliary services. Hence, DCT vendors should not only strengthen their product offerings but also up their game in delivering auxiliary services.

With the exponential rise in DCT adoption, new players are rapidly entering the DCT landscape. In this marketplace, how can vendors offer value and stay on top of the competition? Our analysis reveals the following five areas that can help DCT vendors elevate their offerings above others:

Slide2

  • Inorganic growth – Considering the speed of digital disruption in the clinical trial landscape, inorganic growth is the fastest way to grow and expand capabilities. Technology-based DCT product vendors are focusing on improving their consultative positioning by combining high-tech and high-science under one platform. Two recent examples are THREAD acquiring Modus Outcomes, an organization that supports eCOA selections, designs patient-centric trials, and fosters scientific delivery of DCTs. Similarly, Clinical Ink acquired Digital Artefacts to enrich the data coming from patient-reported outcomes with situational awareness and active and passive digital assessments

 

  • Partnerships – DCT product vendors increasingly seek to partner with specialists to enhance the delivery of auxiliary services. These unions aim to increase trial efficacy and eliminate risks and delays while improving the experience for patients and site practitioners. Some recent deals include Science 37 collaborating with Foundation Medicine to accelerate the patient selection process for oncology trials. THREAD has entered alliances with Almac Clinical Technologies to reduce trial delays and risks and also with endpoint Clinical to simplify trial operations for site personnel

 

  • Human capital development – Investments in human capital are either focused on designing a simple unified platform for seamless patient experience during trials or on expansion and marketing operations. This has led product vendors to add new positions like Chief Growth Officer, Chief Design Officer, Chief Strategy and Expansion Officer, etc. Medable, Science 37, THREAD, Castor, and ObvioHealth have made significant investments in hiring or opening multiple roles directly or indirectly related to DCT solutions to expand their services and establish strategic partnerships

 

  • Funding – Multiple DCT vendors have raised significant funding to enhance their DCT program. Science 37 has recently become a public-listed company, thereby making enough funds available for DCT expansion and growth. On the same lines, Medable has secured a US$ 304 million Series D funding, taking the total company valuation to just over US$ 2 billion. It plans to use the funds to improve access to clinical trials worldwide and accelerate new drug development. ObvioHealth had raised US$ 31 million in its latest round of funding, while Castor raised US$ 45 million in its series B funding. While ObvioHealth plans to direct funding to enhance its proprietary IT capabilities and make new hires, especially keeping in mind the APAC region, Castor is focusing on accelerating trials and maximizing the impact of research data on patient lives. These activities clearly echo the positive investor sentiments towards DCT solutions

 

  • Geographic expansions – Enterprises are looking for studies that are global or beyond the North American (NA) region, pushing DCT vendors outside their established geographies into the Europe, Middle East, and Africa (EMEA) and Asia Pacific (APAC) markets. Both THREAD and Medable have established offices in Dublin, Ireland to expand their presence and grow the market for decentralized trials in the EMEA region. ObvioHealth has partnered with Anatara Lifesciences to launch DCTs in Australia, and Science 37 has partnered with CMIC Holdings to enable and advance its DCT offerings for Japan and the APAC region

The age of decentralized trials has begun, and sponsors are shifting away from the site-anchored approach to hybrid or completely decentralized trials. They are looking to convert their piecemeal deployments into a comprehensive strategy aimed at enhancing the trial experience for patients, sponsors, and CROs.

To cater to this rising demand, DCT product vendors need to leverage advancements in digital technology and enhance their value proposition. With a deep focus on inorganic growth, partnerships, human capital, funding, and geographic expansions, providers can offer a seamless DCT experience in 2022 and well into the future.

What areas should product vendors focus on to stay ahead in the DCT ecosystem? Reach out to [email protected] and [email protected] to discuss.

Explore more information about DCT adoption trends and providers. Learn more

How can we engage?

Please let us know how we can help you on your journey.

Contact Us

"*" indicates required fields

Please review our Privacy Notice and check the box below to consent to the use of Personal Data that you provide.